Overview

Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

Status:
Not yet recruiting

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

This trial will assess the safety and tolerability of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab in unresectable or metastatic hepatocellular carcinoma. Phase 2 will assess the efficacy of this combination therapy in unresectable or metastatic hepatocellular carcinoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Rochester

Treatments:

Atezolizumab
Bevacizumab